Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection - 23/06/21

Doi : 10.1016/j.neurol.2021.05.001

K. Bigaut ^a,^b,⁎ , L. Kremer ^a,^b, M. Fleury ^a, L. Lanotte ^a,^b, N. Collongues ^a,^b, J. de Seze ^a,^b
^a Department of Neurology, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France
^b Clinical Investigation Center, hôpitaux universitaires de Strasbourg, Strasbourg, France

^⁎Corresponding author.

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Wednesday 23 June 2021
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Objective

To analyze the humoral response after COVID-19 vaccination in patients with multiple sclerosis (MS) according to disease-modifying treatments (DMTs) and in comparison with the humoral response after SARS-CoV-2 infection.

Methods

We included 28 MS patients with serological results after COVID-19 vaccination (Pfizer-BioNTech or Moderna ARNm) and 61 MS patients with serological results after COVID-19 (COVID-19 group) among patients followed up at the MS Center of Strasbourg, France, between January and April 2021. The primary endpoint was the IgG index according to DMTs (anti-CD20 mAb, sphingosine 1-phosphate receptor [S1PR] modulator and other treatments) and COVID-19 vaccine or COVID-19 groups.

Results

In the vaccinated MS patients, the median IgG index was lower in patients treated with anti-CD20 mAb and in patients treated with S1PR modulator compared to patients receiving other or no DMTs (4.80 [1.58–28.6], 16.5 [16.3–48.5], 1116 [434–1747] and 1272 [658–1886], respectively, P<0.001). Similar results were found for MS patients after COVID-19.